Ronald Boellaard
Amsterdam University Medical Centers, Amsterdam UMC Location VUmc
Papers
4
Total Citations
315
H-Index
4
About
Ronald Boellaard is a leading authority in quantitative PET imaging, with a primary focus on prostate cancer. His research centers on advancing PSMA PET/CT for improved cancer staging, risk stratification, and treatment guidance. Boellaard’s major contributions include pioneering the use of machine learning to analyze [18F]DCFPyL PET radiomics, enabling non-invasive risk stratification in primary prostate cancer—a study that has garnered 135 citations. He also led the landmark SALT trial (106 citations), demonstrating the superior accuracy of PSMA PET/CT for pelvic lymph-node staging prior to extended dissection, and the DeTeCT trial (47 citations), which explored the feasibility of PSMA-targeted biopsy by comparing PET findings with radical prostatectomy histopathology. His work has further established that standardised uptake values (SUVmax) on PSMA PET/CT are significantly associated with oncological outcomes, as shown in a 2022 study (27 citations). Boellaard’s research has been instrumental in validating quantitative PET metrics as reliable biomarkers, directly impacting clinical decision-making in prostate cancer management. His contributions have shaped international guidelines and continue to influence the integration of molecular imaging into precision oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4